BRIEF published on 09/24/2024 at 23:05, 8 months 6 days ago Theralase clôture un placement privé sans intermédiaire et émet des options sur actions Placement Privé Sans Intermédiaire Technologies Théralase Options Sur Actions Financement De La Recherche Clinique Étude Sur Le Cancer De La Vessie
BRIEF published on 09/24/2024 at 23:05, 8 months 6 days ago Theralase Closes Non-Brokered Private Placement and Issues Stock Options Stock Options Non-brokered Private Placement Theralase Technologies Clinical Research Funding Bladder Cancer Study
PRESS RELEASE published on 09/24/2024 at 23:00, 8 months 6 days ago Theralase(R) Closes Non-Brokered Private Placement and Issues Stock Options Theralase Technologies Inc. successfully closes Non-Brokered Private Placement offering of units for cancer research and development Private Placement Pharmaceutical Company Theralase Technologies Inc. Clinical Study Cancer Research
BRIEF published on 09/19/2024 at 23:10, 8 months 11 days ago Theralase® prolonge ses mandats Extension Bourse De Croissance TSX Technologies Théralase Bons De Souscription D'actions Développement Pharmaceutique
BRIEF published on 09/19/2024 at 23:10, 8 months 11 days ago Theralase® Extends Warrants Share Purchase Warrants TSXV Extension Theralase Technologies Pharmaceutical Development
PRESS RELEASE published on 09/19/2024 at 23:05, 8 months 11 days ago Theralase(R) Extends Warrants Theralase Technologies Inc. plans to extend expiry date of 10,000,000 share purchase warrants from Sept 22, 2024, to Sept 22, 2027. Warrants issued in 2022 at $0.35/share. TSXV approval pending TSX Venture Exchange Expiry Date Extension Theralase Technologies Inc. Share Purchase Warrants Clinical Stage Pharmaceutical Company
BRIEF published on 09/03/2024 at 13:05, 8 months 27 days ago Ruvidar(TM) Proven More Effective Than Acyclovir in Destruction of Herpes Simplex Virus Theralase Ruvidar Antiviral Drug HSV-1 Acyclovir
BRIEF published on 09/03/2024 at 13:05, 8 months 27 days ago Ruvidar(TM) s'avère plus efficace que l'acyclovir dans la destruction du virus de l'herpès simplex Theralase Ruvidar Médicament Antiviral HSV-1 Acyclovir
PRESS RELEASE published on 09/03/2024 at 13:00, 8 months 27 days ago Ruvidar(TM) Proven More Effective Than Acyclovir in Destruction of Herpes Simplex Virus Theralase Technologies Inc. announces preclinical superiority of Ruvidar TM in destroying HSV-1 virus, seeking partnerships for commercial development Theralase Technologies Inc. Preclinical Study Partnerships Ruvidar TM HSV-1 Virus
BRIEF published on 08/28/2024 at 13:05, 9 months 2 days ago Rutherrin® augmente l'efficacité de la chimiothérapie contre le cancer du poumon Theralase® Technologies Inc. Chimiothérapie CPNPC Rutherrine® Cisplatine
Published on 05/31/2025 at 06:16, 3 hours 35 minutes ago Moderna Receives U.S. FDA Approval for COVID-19 Vaccine mNEXSPIKE
Published on 05/31/2025 at 03:30, 6 hours 21 minutes ago Avant Brands Inc. Announces Voting Results From 2025 Annual General Meeting of Shareholders
Published on 05/31/2025 at 01:45, 8 hours 6 minutes ago GLG Life Tech Corporation Reports 2025 First Quarter Financial Results
Published on 05/30/2025 at 23:10, 10 hours 41 minutes ago CORRECTION: Nextech3D.ai Migrates MAP Dynamics to AWS, Enabling Scalable AI Architecture and Accelerated Deployment
Published on 05/30/2025 at 23:00, 10 hours 51 minutes ago Battery X Metals Achieves Full Capacity Recovery on a Real-World Imbalanced Battery from the #2 Out-of-Warranty Electric Vehicle Model in the United States in Preliminary Trial
Published on 05/31/2025 at 09:15, 35 minutes ago Hong Kong-headquartered International Mediation Body Established
Published on 05/30/2025 at 21:22, 12 hours 28 minutes ago CPI PROPERTY GROUP publishes financial results for the first quarter of 2025
Published on 05/30/2025 at 20:30, 13 hours 21 minutes ago IUTE GROUP ISSUES EUR 140 MILLION NEW SENIOR SECURED EUR 2025/2030 BONDS – Strong demand from existing investors and new subscriptions
Published on 05/30/2025 at 18:05, 15 hours 46 minutes ago Eurobattery Minerals will submit additional documentation for the EPA at the end of June
Published on 05/30/2025 at 18:04, 15 hours 46 minutes ago Funding Circle Holdings plc: POS-Transaction in Own Shares
Published on 05/30/2025 at 22:00, 11 hours 51 minutes ago Information on the Annual Financial Statements
Published on 05/30/2025 at 18:14, 15 hours 36 minutes ago Emova Group - Rapport annuel de Durabilité 23/24
Published on 05/28/2025 at 23:00, 2 days 10 hours ago Standstill Commitments to hold shares of the company
Published on 05/28/2025 at 23:00, 2 days 10 hours ago Engagements collectifs de conservation de titres de la société
